Agreement - February 22, 2017
AstraZeneca in agreement with TerSera Therapeutics
AstraZeneca has entered into an agreement with TerSera Therapeutics (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. Zoladex is an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders. It was first approved in the US and Canada in 1989. […]
Agreement - February 22, 2017
Sobi enters distribution agreement
Swedish Orphan Biovitrum (Sobi) announces that the company has entered into a 3-year agreement with Valeant Pharmaceuticals Ireland for the distribution of Ammonul (sodium phenyl acetate and sodium benzoate) injection in Europe, the Middle East and North Africa. The new agreement replaces the current distribution agreement with Valeant Pharmaceuticals North America LLC for the same […]
Agreement - February 22, 2017
Brighter signs agreement with Sonat
Brighter has selected Sonat as its development partner for the upcoming launch of Actiste, Brighter’s connected diabetes solution. Sonat specializes in developing, managing and running logistics processes, and will together with Brighter develop a strong logistics platform that facilitates growth and international expansion. Under the agreement, Sonat will take on a partner role and drive […]
Agreement - February 16, 2017
Senzime signs distribution agreement
Senzime has entered distribution agreements for the commercialization of TetraGraph with Wardray Premise, who will be the exclusive distributor in the UK and Ireland and LSR Healthcare who will be the exclusive distributor in Australia and New Zealand. Compensation to distributors will be paid on a “per-unit sold” basis, and is in line with current […]
Agreement - February 14, 2017
Enzymatica enters partnership agreement
Enzymatica enters into partnership agreement with STADA Arzneimittel which grants STADA exclusive rights to sell, market and distribute Enzymatica’s common cold product ColdZyme in Germany. Stada is a global pharmaceutical company, headquartered in Germany, with a strong presence in Europe and leading positions in the cough and cold category in Germany, UK, and Russia. “We […]
Agreement - February 13, 2017
BC Platforms enters new partnership
BC Platforms has signed a partnership with Dartmouth-Hitchcock Medical Center’s laboratory of Clinical Genomics and Advanced Technology in the Department of Pathology & Laboratory Medicine in the US, focused on providing data management solutions in cancer research. BC Platforms will link clinical and genomic data from Dartmouth-Hitchcock’s tumour biobank to enable rapid statistical analysis of […]
